144 related articles for article (PubMed ID: 23211261)
1. Achievement of cholesterol targets and prescribing of higher-cost statins: a cross-sectional study in general practice.
Fleetcroft R; Schofield P; Duerden M; Ashworth M
Br J Gen Pract; 2012 Dec; 62(605):e815-20. PubMed ID: 23211261
[TBL] [Abstract][Full Text] [Related]
2. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
3. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'.
Ashworth M; Lloyd D; Smith RS; Wagner A; Rowlands G
J Public Health (Oxf); 2007 Mar; 29(1):40-7. PubMed ID: 17071815
[TBL] [Abstract][Full Text] [Related]
4. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target.
Lum CJ; Nakagawa K; Shohet RV; Seto TB; Taira DA
Hawaii J Med Public Health; 2017 Apr; 76(4):99-102. PubMed ID: 28428922
[TBL] [Abstract][Full Text] [Related]
6. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
[TBL] [Abstract][Full Text] [Related]
7. Statin prescribing in Northern Ireland and England pre and post introduction of the quality and outcomes framework.
Alabbadi I; Crealey G; Turner K; Rafferty T; Keenan L; Murray P; McElnay JC
Pharm World Sci; 2010 Feb; 32(1):43-51. PubMed ID: 19882233
[TBL] [Abstract][Full Text] [Related]
8. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002.
Teeling M; Bennett K; Feely J
Br J Clin Pharmacol; 2005 Feb; 59(2):227-32. PubMed ID: 15676046
[TBL] [Abstract][Full Text] [Related]
9. Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
Hickman J
Br J Gen Pract; 2010 Jan; 60(570):50-2. PubMed ID: 20040169
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
11. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
12. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
13. Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis.
Fleetcroft R; Schofield P; Ashworth M
BMC Health Serv Res; 2014 Sep; 14():414. PubMed ID: 25240604
[TBL] [Abstract][Full Text] [Related]
14. Prescribing statins in general practice: who decides?
Steel N; Fleetcroft B; Hassan Y
Br J Gen Pract; 2017 Jun; 67(659):246-247. PubMed ID: 28546390
[No Abstract] [Full Text] [Related]
15. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
16. Can cheap generic statins achieve national cholesterol lowering targets?
Petty D; Lloyd D
J Health Serv Res Policy; 2008 Apr; 13(2):99-102. PubMed ID: 18416915
[TBL] [Abstract][Full Text] [Related]
17. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
19. A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care.
Lowrie R; Lloyd SM; McConnachie A; Morrison J
PLoS One; 2014; 9(11):e113370. PubMed ID: 25405478
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
